Relevant data are within the manuscript and its Supporting Information files. RNAseq data <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139040>.

Introduction {#sec001}
============

Glycogen Synthase Kinase-3 (GSK-3) is a highly conserved protein kinase that has orthologs in all metazoans, with proteins from distant species such as flies and humans displaying more than 90% sequence similarity in the protein kinase domain \[[@pone.0236679.ref001], [@pone.0236679.ref002]\]. Initially identified as an enzyme involved in the regulation of glycogen metabolism, a key role for the *Drosophila* orthologue encoded by the *shaggy* (*sgg*) locus in embryonic segmentation \[[@pone.0236679.ref003]\] established GSK-3 at the heart of the Wnt signalling pathway in flies and vertebrates \[[@pone.0236679.ref004]\]. In brief, GSK-3 kinase activity acts to negatively regulate Wnt signalling by phosphorylating β-catenin, Armadillo (Arm) in *Drosophila*, such that it is ubiquitinylated and subsequently degraded by the proteasome. When Wnt signalling is active, GSK-3 is inactivated, Arm is stabilized and translocates to the nucleus where it binds to the Tcf transcription factor to activate Wnt responsive genes \[[@pone.0236679.ref005]\]. Considerable work from many laboratories has established that GSK-3 and Wnt signalling is pivotal for cell differentiation and morphogenesis across the Metazoa \[[@pone.0236679.ref005], [@pone.0236679.ref006]\].

In vertebrates, there are two major isoforms of GSK-3, alpha and beta, each encoded by independent paralogous genes. While these isoforms share considerable homology in the kinase domain (85% overall identity, 98% within the kinase domains) \[[@pone.0236679.ref007]\], they show major differences at their termini with GSK-3α containing a large glycine-rich N-terminal region that is absent in GSK-3β \[[@pone.0236679.ref002]\]. Loss of GSK-3β in mice results in late embryonic lethality with liver, cardiac and craniofacial defects \[[@pone.0236679.ref008]--[@pone.0236679.ref010]\], and in Xenopus, expression of a kinase dead version of GSK-3β resulted in axis formation defects \[[@pone.0236679.ref011]\]. In addition, GSK-3β heterozygous mice exhibit a range of phenotypes, particularly in aspects of metabolism, homeostasis and nervous system function \[[@pone.0236679.ref012]--[@pone.0236679.ref015]\]. In contrast, loss of function GSK-3α mice are viable but show alterations in glucose metabolism \[[@pone.0236679.ref016]\] and abnormalities in brain structure and behaviour \[[@pone.0236679.ref017], [@pone.0236679.ref018]\]. Interestingly, there is evidence that the mammalian isoforms show both partially redundant and antagonistic interactions \[[@pone.0236679.ref012], [@pone.0236679.ref019]--[@pone.0236679.ref021]\] with the current view that they act at least partially redundantly in early embryonic Wnt signalling \[[@pone.0236679.ref022]\]. In contrast to vertebrates, the *Drosophila* genome contains a single major GSK-3 locus, *sgg*, that shows considerable complexity, with 17 annotated transcripts encoding 10 different protein isoforms predicted ([Fig 1A and 1B](#pone.0236679.g001){ref-type="fig"}). A second GSK-3 enzyme is encoded by the *gasket* locus, a retrotransposed gene whose expression is largely restricted to the testis \[[@pone.0236679.ref023]\] and is not considered further here. Sgg proteoforms differ at their N termini (5 alternatives), at internal exons and at the C terminus (3 alternatives). At the C terminus, Sgg-PD is unique among the proteoforms and was previously identified as Sgg46 \[[@pone.0236679.ref024]\]. The remaining nine proteoforms containing either a short C terminus, typified by Sgg-PB (Sgg10), or a longer C terminus typified by Sgg-PA (Sgg39). The longer isoform contains a glycine-rich region that is analogous to the N-terminal domain of the vertebrate GSK-3α. The role of this domain is currently not well understood but is predicted to contain an ANCHOR binding region \[[@pone.0236679.ref025]\] and two short MATH domain interaction motifs, both thought to be important in protein interactions \[[@pone.0236679.ref026]\] ([Fig 1C](#pone.0236679.g001){ref-type="fig"}).

![**A)** simplified map of *shaggy* locus showing the major proteoforms (from FlyBase). Diamonds indicate the position of insertion sites tagged by CRISPR/Cas9 with the colour representing the tag used. **B)** Length of each of the major Sgg proteoforms in amino acids and an indication of proteoforms sharing the same amino acid sequence (from FlyBase). **C)** Amino acid sequence of the C terminal exon differentiating isoform A from isoform B. The underlined sequence is a predicted ANCHOR binding region, lowercase letters indicate predicted MATH domain interaction motifs. **D)** modENCODE RNAseq timecourse of relative expression levels of transcripts encoding the major Sgg-PA Sgg-PB isoforms. The X axis indicates the modENCODE samples collected with the first 12 representing 2hr intervals across embryogenesis. Dotted line indicates the end of embryonic development.](pone.0236679.g001){#pone.0236679.g001}

In *Drosophila*, *sgg* is known to have a variety of developmental roles and interacts with a number of signalling pathways including Wnt, Hedgehog, Notch and Insulin \[[@pone.0236679.ref027]--[@pone.0236679.ref029]\], as well as being implicated in a variety of other cellular processes \[[@pone.0236679.ref030]\]. Null mutations in *sgg* exhibit a maternal effect lethal phenotype with a strong segment polarity defect in embryos lacking zygotic and maternal Sgg, as well as defects in the central and peripheral nervous systems \[[@pone.0236679.ref031]\]. In addition, analysis of a wide range of other alleles has reveal phenotypes in diverse tissues, for example in the macrochaetes, mechanosensory bristles found on the adult thorax, where it has been shown to phosphorylate key transcription factors \[[@pone.0236679.ref032]\]. However, despite the considerable focus on the role of *sgg* in development, little is known about how particular proteoforms contribute to specific functions. Previous work indicates that Sgg-PB (Sgg10) is an important proteoform, maternally contributed and detected throughout development into adults \[[@pone.0236679.ref033]\]. In contrast, Sgg-PA (Sgg39) has more limited expression, it does not appear to be maternally contributed ([Fig 1D](#pone.0236679.g001){ref-type="fig"}). and is not detected in wing imaginal disks, where the adult macrochaetes develop. A third major isoform, Sgg-PD (Sgg46), contains a C-terminal domain that includes a caspase-cleavage site. It appears to be dispensable for viability but has a role in sensory organ precursor development \[[@pone.0236679.ref024], [@pone.0236679.ref033]\]. Rescue experiments in *Drosophila* indicate that expression of a Sgg-PB isoform can fully rescue *sgg* null phenotypes and that mammalian GSK-3β but not GSK-3α can provide partial rescue of some, but not all null phenotypes, emphasising the difference between the mammalian genes and pointing to functional differences between Sgg proteoforms \[[@pone.0236679.ref028]\].

The complexity of the *sgg*, locus in *Drosophila* with its multiple proteoforms and the apparent differences between GSK-3 paralogs in vertebrates raises the question of how different GSK-3 proteoforms contribute to the functions of this key kinase during development and in homeostasis. In particular, there has been a general debate as to whether protein isoforms encoded by the multiple splice forms of a particular gene are produced and functional. One extreme, based on evidence from high throughput mass-spectrometry or literature curation of verified proteoforms, contends that most genes encoding multiple alternatively spliced isoforms only produce a single functional proteoform \[[@pone.0236679.ref034], [@pone.0236679.ref035]\]. In contrast, an alternative view is that alternatively spliced isoforms generate proteoforms with functionally distinct properties in terms of spatial or temporal expression, or their interaction repertoires \[[@pone.0236679.ref036], [@pone.0236679.ref037]\]. To help address the role of alternative Sgg proteoforms in *Drosophila* and the developmental roles GSK-3 plays, as well as contributing to the debate surrounding the functionality of splice isoforms, we used a CRISPR-Cas9 based genome engineering strategy to tag specific Sgg proteoforms. We introduced fluorescent protein or affinity tags into the endogenous *sgg* locus in *Drosophila* \[[@pone.0236679.ref038]\], altogether tagging eight different exons. This allowed us to follow the expression of Sgg proteoforms across embryonic development by immunohistochemistry and/or fluorescence microscopy, revealing unique and specific expression for each of the tagged proteoforms. Focusing on the major C terminal domains, we show that the short form (Sgg-PB) is ubiquitously expressed across embryogenesis and is essential for viability. In contrast, the long form (Sgg-PA) is specifically expressed in the developing nervous system and is not required for viability. Furthermore, using the tagged lines to identify interacting proteins for each proteoform class we found a different set of interactors. This agrees with an analysis of mammalian GSK-3α and β interactions using a yeast 2-hybrid approach which found a different set of interacting proteins for these closely related proteins \[[@pone.0236679.ref039]\]. We found that the loss of major proteoforms is not always compensated by other isoforms and can lead to age-related pathologies including accelerated senescence. Taken together, our work suggests that the transcript complexity of the *Drosophila sgg* locus reflects functionally relevant differences in the spatial and temporal expression of GSK-3 as well as functional differences between major proteoforms.

Results and discussion {#sec002}
======================

In vivo tagging of major Sgg proteoforms {#sec003}
----------------------------------------

In order to determine the expression and localisation of specific Sgg proteoforms we used CRISPR/Cas9 genome engineering to introduce different in-frame protein tags into specific exons at the endogenous *sgg* locus \[[@pone.0236679.ref038]\]. We first focused on the major C terminal proteoforms represented by Sgg-PA and Sgg-PB, constructing fly lines containing a 3xFLAG-StrepTagII-mVenus-StrepTagII (FSVS) cassette just before the termination codon. We have previously utilised this cassette in a large-scale protein trap screen \[[@pone.0236679.ref040]\] and found it was tolerated by a wide range of different *Drosophila* proteins *in vivo*. In both cases the lines we generated were homozygous or hemizygous viable and fertile. Using an antibody against the FLAG epitope we first examined the expression of each tagged proteoform in the *Drosophila* embryo via immunohistochemistry. With Sgg-PA we found little or no expression during early development but by stage 9 (germband extension) we observed strong and specific expression in the developing CNS of the trunk and then brain. As development proceeded expression became prominent in the elaborating PNS and was particularly strong in the chordotonal organs, where it continued to the end of embryogenesis ([Fig 2E and 2H](#pone.0236679.g002){ref-type="fig"}). Looking more closely we observed that in the chordotonal organs staining was associated with the cell bodies and extended into the ciliated endings. (arrows in [Fig 2M and 2P](#pone.0236679.g002){ref-type="fig"}). Towards the end of embryogenesis, we observed specific staining in a subset of cells in the developing brain and in the anterior commissural bundle ([S1 Fig](#pone.0236679.s001){ref-type="supplementary-material"}). In contrast, we found strong and ubiquitous staining in the Sgg-PB lines in the early embryo, as expected from the strong maternal contribution detected by RNA-seq analysis ([Fig 1D](#pone.0236679.g001){ref-type="fig"}), that continued until germ band retraction ([Fig 2C and 2F](#pone.0236679.g002){ref-type="fig"}). Demonstrating that the ubiquitous strong staining reflects Sgg-PA expression, we live imaged embryos carrying an mCherry tagged Sgg-PA and observed similar ubiquitous expression in the blastoderm ([S1F Fig](#pone.0236679.s001){ref-type="supplementary-material"}). At later stages expression was prominent in the hindgut, midgut and salivary glands ([Fig 2I](#pone.0236679.g002){ref-type="fig"}**)**. At higher magnification in stage 11--13 embryos (germ band retraction), we observed staining in the developing muscles ([Fig 2N](#pone.0236679.g002){ref-type="fig"}) and epidermis ([Fig 2O](#pone.0236679.g002){ref-type="fig"}).

![Immunohistochemistry and live imaging of tagged Sgg-PA and -PB proteoforms.\
All stainings are with anti-FLAG. **(A, D and G)** wild type embryos at stage 5--6 (blastoderm), 10--11 (extended germ band) and 16 (late embryogenesis) respectively. **(B, E and H)** tagged Sgg-PA at similar stages showing expression in the developing CNS (arrows in E), mature CNS and PNS (arrow and arrowhead in H). **(C, F and I)** tagged Sgg-PB at equivalent stages showing ubiquitous expression at the blastoderm **(C)** and germband extension stages **(F),** followed by localised expression in hindgut (arrow in I), midgut (arrowhead in I) and salivary glands (white arrow in I). **(J-L)** live confocal images of late stage embryos. Wild type showing gut autofluorescence (**J)**, Sgg-PA^FSVS^ showing prominent CNS expression **(K)**, Sgg-PB^FSVS^ showing mesoderm expression **(L)**. **(M)** lateral view of abdominal chordotonal organs from a stage 15 Sgg-PA embryo. **(N and O)** lateral view of the mesoderm **(N)** and epidermis **(O)** from a stage 14 Sgg-PB embryo. **P)** lateral view of YFP expression in abdominal chordotonal organs of a stage 15 Sgg-PA embryo. **(Q)** lateral view of YFP expression the epidermis of a stage 15 Sgg-PB embryo. All embryos are lateral views with anterior to the left. Scale bar in A = 100μm (applies to A-L), Scale bar in M = 20μm (applies to M-Q).](pone.0236679.g002){#pone.0236679.g002}

To confirm the localisation observed with the immunohistochemistry, we examined the FSVS tagged versions of Sgg-PA and Sgg-PB by confocal imaging unfixed samples. We found very similar, if not identical, localisation to that obtained by immunohistochemistry ([Fig 2K and 2L](#pone.0236679.g002){ref-type="fig"}). In particular the fluorescence allowed much clearer visualisation of Sgg-PA throughout the chordotonal organs ([Fig 2P](#pone.0236679.g002){ref-type="fig"}) and Sgg-PB in the musculature ([Fig 2Q](#pone.0236679.g002){ref-type="fig"}). We also generated alternatively tagged versions of each proteoform by replacing the YFP tag with mCherry. We generated embryos heterozygous for either Sgg-PA^YFP^/Sgg-PB^mCh^ ([Fig 3A and 3C](#pone.0236679.g003){ref-type="fig"}) or Sgg-PA^mCh^/Sgg-PB^YFP^ ([Fig 3B and 3D](#pone.0236679.g003){ref-type="fig"}) and imaged these by confocal microscopy. While in general the mCherry signal was significantly weaker that the YFP, we were able to confirm and extend our immunohistochemistry observations. The fluorescent reporters confirmed the strong localisation of Sgg-PA to the central nervous system and prominently in the PNS as well as Sgg-PB in the epidermis and mesoderm ([Fig 3E and 3F](#pone.0236679.g003){ref-type="fig"}), particularly in the epidermis, Sgg-PB appeared to give a more punctate appearance (Figs [3E](#pone.0236679.g003){ref-type="fig"} and [S1G](#pone.0236679.s001){ref-type="supplementary-material"}).

![Fluorescence imaging of tagged Sgg proteoforms.\
**(A and C)** heterozygous stage 17 female embryos carrying Sgg-PA tagged with YFP and Sgg-PB tagged with mCherry showing Sgg-PA expression in CNS **(A)** and PNS **(C)** with weaker ubiquitous expression of Sgg-PB. **(B and D)** stage 17 heterozygous female embryos carrying reciprocally tagged lines (Sgg-PA-mCherry, Sgg-PB-YFP) highlighting Sgg-PA in the CNS **(B)** and PNS **(D)** and Sgg-PB in the mesoderm **(D)**. **(E and F)** close up view of Sgg-PA in chordotonal organs (YFP in E and mCherry in F) and punctate epidermal Sgg-PB (mCherry in E) and mesodermal Sgg-PB (YFP in F). All embryos oriented anterior to the left, dorsal to the top. Scalebar in B = 100μm (applies to A-D), Scale bar in E = 20μm (applies to E and F).](pone.0236679.g003){#pone.0236679.g003}

Tagging other Sgg proteoforms {#sec004}
-----------------------------

We extended our analysis to examine other Sgg proteoforms, introducing exon specific 3xFLAG-StrepTagII tags into the endogenous *sgg* locus ([Fig 1](#pone.0236679.g001){ref-type="fig"}, [S1 Table](#pone.0236679.s003){ref-type="supplementary-material"}). We tagged the C-terminus of the first exon of Sgg-PD (which also tags -PP and -PQ); the first coding exon of Sgg-PG (also tags -PR), the unique terminal exon of Sgg-PO, a unique internal exon of Sgg-PP and an internal exon of Sgg-PQ (shared with -PM, -PP and -PR). Finally, Sgg-PM is predicted to initiate with a valine rather than a methionine and we tagged a unique exon in this proteoform to confirm the translation from a non-standard initiation codon. All of the tagged lines we generated were homozygous or hemizygous viable and fertile, and we again examined expression in fixed samples by immunohistochemistry with a monoclonal antibody recognising the FLAG epitope ([S2 Fig](#pone.0236679.s002){ref-type="supplementary-material"}). In contrast to the -PA and -PB tagged lines we noticed that, apart from Sgg-PD, the expression levels of the other proteoforms was generally weaker and mostly restricted to particular tissues.

### Sgg-PD {#sec005}

This variant shows early expression that is largely restricted to mesoderm ([S2D Fig](#pone.0236679.s002){ref-type="supplementary-material"}) and becomes more prominent at stage 9 ([S2E Fig](#pone.0236679.s002){ref-type="supplementary-material"}). At later stages the expression of Sgg-PD is generally weak and ubiquitous with elevated levels found in the CNS, posterior spiracles, Malpighian tubules, proventriculus and salivary glands ([S2F and S2V Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

### Sgg-PG and -PR {#sec006}

These proteoforms share a unique amino terminus and have either the long (-PR) or short (-PG) C termini described above, they also differ in a short internal exon but our tagging does not differentiate between these ([S1 Table](#pone.0236679.s003){ref-type="supplementary-material"}). We did not detect any strong expression during early stages, but by mid-embryogenesis we observed transient mesoderm expression ([S2H Fig](#pone.0236679.s002){ref-type="supplementary-material"}) followed by later expression in the hindgut ([S2I Fig](#pone.0236679.s002){ref-type="supplementary-material"}), foregut and the anterior region of the pharynx ([S2W Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

### Sgg-PM {#sec007}

This proteoform is predicted to initiate with an unconventional start codon, a valine rather than a methionine, and shares a C terminus with Sgg-PA. We found no early expression of this proteoform. Late in development we observed expression in the pharynx, proventriculus and weakly in the hindgut ([S2L Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

### Sgg-PO {#sec008}

This Sgg-PO proteoform has a unique C-terminus ([Fig 1](#pone.0236679.g001){ref-type="fig"}), and is not detected during early stages but again shows detectable expression in the mesoderm ([S2N Fig](#pone.0236679.s002){ref-type="supplementary-material"}) from stage 9 and at later stages in the hindgut, posterior spiracles and prominently in the proventriculus ([S2O and S2X Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

### Sgg-PP {#sec009}

This proteoform shares the N-terminal exon of Sgg-PD and the short C-terminal exon but has a short unique exon that we tagged. We did not find any expression during early embryogenesis, although there appears to be faint staining in the mesoderm at stage 9 ([S2Q Fig](#pone.0236679.s002){ref-type="supplementary-material"}), but we did observe expression in the hindgut and anterior midgut of late embryos ([S2R and S2Y Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

### Sgg-PQ {#sec010}

We tagged this proteoform at an internal exon shared with--PR, -PP, and--PM. These proteoforms were not detected during early embryogenesis but at later stages it was is prominent in the salivary glands and proventriculus ([S2U Fig](#pone.0236679.s002){ref-type="supplementary-material"}).

Taken together, our tagging strategy has revealed dynamic and tissue-specific expression of different Sgg proteoforms during embryogenesis. Our most striking finding is the clear difference in expression of the major C-terminus proteoforms exemplified by Sgg-PA and Sgg-PB, which, as we describe above, may correspond to the GSK-3α and GSK-3β proteins encoded by separate genes in vertebrate genomes. We therefore elected to generate specific loss of function mutations in each of these major isoforms by separately deleting their specific C-terminal exons. A further noticeable feature of the proteoform expression was the localisation of different tagged proteoforms in the developing digestive system, particularly in the proventriculus and hindgut. While it has been shown that *sgg* expression is enriched in particular regions of the adult gut, particularly the crop and hindgut \[[@pone.0236679.ref041]\], there have been relatively few reports of functional roles for *sgg* in the gut \[[@pone.0236679.ref042], [@pone.0236679.ref043]\] or other specific tissues in the embryo \[[@pone.0236679.ref044]\]. Finally, the extensive early mesoderm expression shown by several proteoforms is consistent with the previously established role for *sgg* and Wnt signalling in embryonic muscle cell progenitors\[[@pone.0236679.ref045]\].

Proteoform specific mutations and transcriptomics {#sec011}
-------------------------------------------------

We used CRISPR-Cas9 genome engineering to generate in locus deletions to remove the C-terminal exons specific for the Sgg-PA or Sgg-PB proteoform families. We completely removed the unique exons, replacing them with a 3Px3 driven DsRED marker, flanked by LoxP sites, that was subsequently removed by the activity of Cre recombinase to leave the remainder of the locus largely unaltered \[[@pone.0236679.ref046]\]. In this way we generated Sgg-PB mutations, where the following upstream exon unique for isoform Sgg-PA was left intact. Similarly, we removed the last unique exon for isoform Sgg-PA ensuring the flanking sequences were not affected. Both of the exon deletions were confirmed by genotyping via PCR and sequencing.

Deletion of the Sgg-PA class proteoforms (*sgg*^*isoA*^) resulted in flies that were viable and fertile, whereas loss of the Sgg-PB class proteoforms (*sgg*^*isoB*^) resulted in late embryo/early larval lethality. We note that in the case of *sgg*^*isoA*^, progeny from homozygous mothers lack both maternal and zygotic contributions and are thus completely null, whereas progeny from hemizygous *sgg*^*isoB*^ mothers have a maternal contribution of wild type transcript or protein.

We examined mutant lines by immunostaining to determine any effects on CNS and PNS development and only observed minor defects in a small percentage of progeny (\<5%). Examination of larval cuticles revealed a similar low frequency of defects, with the very occasional appearance of animals resembling *sgg* loss of function phenotypes (\<1%). We conclude that the unique C-terminal extension defining the Sgg-PA class of proteoforms is dispensable for normal development, a similar situation as seen in vertebrates with the loss of GSK-3α. We presume that in this case, ubiquitous expression of the shorter Sgg-PB class of proteoforms is able to provide sufficient Sgg function in the nervous system. In contrast, loss of the Sgg-PB class terminal exon is lethal and either cannot be rescued by the longer C-terminus or selection of the Sgg-PA terminal exon is tissue specific and unable to be spliced in some tissues.

To examine whether the loss or reduction of Sgg proteoforms had consequences for gene expression, we performed RNA-seq analysis using RNA extracted from the isoform specific null mutants ([Fig 4A](#pone.0236679.g004){ref-type="fig"}, [S2 Table](#pone.0236679.s004){ref-type="supplementary-material"}). In the case of *sgg*^*isoA*^, embryos from homozygous mothers crossed to hemizygous fathers are completely null for the proteoforms containing this exon and we compared RNA from these embryos with stage matched embryos from the progenitor stock. We performed triplicate biological replicates and after filtering (1.6-fold expression change, p\<0.05) we identified 100 genes with significantly changed expression (26 up and 74 down) with no significant enrichment of any Gene Ontology terms apart from a down-regulation of 6 mitochondria-encoded respiratory chain components (*ATPase-6*, *Cyt-b* and 4 ND subunits) along with 7 other enzymes involved in respiration or redox reactions. Given that *sgg*^*isoA*^ null embryos are viable and fertile the lack of any major effects on gene expression was not unexpected.

![RNA-seq of *sgg* isoform mutants.\
**(A)** heatmaps of significant expression changes in embryos maternally and zygotically null for *sgg*^*isoA*^ and zygotically null for *sgg*^*isoB*^ with significant GO enrichments indicated. (**B)** String interaction map constructed from genes with significantly changed expression in *sgg*^*isoB*^ zygotic nulls showing highly connected networks of peptidases, chaperone functions and cuticle biosynthesis genes (p-values indicated corrected gene ontology enrichments for the indicated terms).](pone.0236679.g004){#pone.0236679.g004}

For the analysis of *sgg*^*isoB*^ we extracted RNA from null hemizygous male embryos derived from heterozygous mothers, identifying these individuals by the lack of a GFP balancer, and compared this with RNA from the progenitor stock. While we expect a rescue of the zygotic mutation by the maternal component, we nevertheless identified 482 genes with significant expression changes (94 up and 388 down) ([S2 Table](#pone.0236679.s004){ref-type="supplementary-material"}). In particular, we noted a strong upregulation of Heat Shock Factor (Hsf) and a number of stress response and chaperone genes, but down regulation of sets of genes implicated in cuticle development and proteolysis. Many of these dysregulated genes form a highly connected network (p \<10e-16, [Fig 4B](#pone.0236679.g004){ref-type="fig"}) indicating that mutants are clearly perturbed at the transcriptional level. We presume these gene expression changes reflect the gradual loss of *sgg*^*isoB*^ maternal product, however, and in line with the lack of overt morphological phenotypes, we note that we found no apparent changes in any major developmental or signalling pathways.

Proteoform-specific interactions {#sec012}
--------------------------------

Since the two major Sgg proteoform classes are expressed in spatially different patterns it is possible that they participate in different pathways, have different protein partners or preferentially act on a different spectrum of substrates. To gain insight into possible unique roles we performed immunopurifications followed by mass spectrometry analysis to identify Sgg-PA and Sgg-PB interactomes. Using our previously described IPAC approach \[[@pone.0236679.ref047]\], we performed independent purifications using the StrepII, FLAG and YFP tags introduced into the *sgg* locus to increase the reliability of the identified interacting partners. In parallel, we also used a protein trap line we had previously generated (*sgg*^*CPTI002603*^) that appears to tag the majority of Sgg proteoforms \[[@pone.0236679.ref040]\], along with a *w*^*1118*^ negative control. We applied the QProt pipeline, a tool for examining differential protein expression, with a p-value cut-off of 0.05 and a requirement that putative interactors be identified in at least 2 out of the 3 independent pull downs after correcting against the wild type control. We identified 20 co-purifying proteins with Sgg^CPTI002603^, 26 with the Sgg-PA and 21 with Sgg-PB ([Table 1](#pone.0236679.t001){ref-type="table"}).

10.1371/journal.pone.0236679.t001

###### Significant interacting proteins identified by IPAC-MS for Sgg-PA, Sgg-PB and the Sgg^CPTI115553^ protein trap line.

![](pone.0236679.t001){#pone.0236679.t001g}

  Sgg-PA        Sgg-PB                                                 Sgg-CPTI                                                                                                                                          
  ------------- ------------------------------------------------------ ---------- ----------------- -------------------------------------------- ---------- ----------------- ------------------------------------------ ----------
  FBgn0035853   Ubiquitin conjugating enzyme E2M                       1.42E-03   FBgn0035621       uncharacterized protein                      6.50E-05   FBgn0000181       Bicaudal                                   2.00E-06
  FBgn0035621   uncharacterized protein                                1.45E-03   FBgn0004649       Yolkless                                     2.44E-04   FBgn0010774       RNA and export factor binding protein 1    5.48E-03
  FBgn0033879   uncharacterized protein                                3.67E-03   FBgn0250848       26-29kD-proteinase                           3.11E-04   FBgn0035621       uncharacterized protein                    2.29E-02
  FBgn0029969   uncharacterized protein                                9.08E-03   FBgn0285925       Fasciclin 1                                  3.53E-04   FBgn0003391       Shotgun                                    2.84E-02
  FBgn0029785   Ribosomal protein L35                                  1.07E-02   FBgn0285954       Cabeza                                       8.97E-04   FBgn0010215       Alpha Catenin                              2.94E-02
  FBgn0039857   Ribosomal protein L6                                   1.10E-02   FBgn0035909       Ergic53                                      1.32E-03   FBgn0030136       Ribosomal protein S28b                     2.99E-02
  FBgn0020660   eukaryotic translation initiation factor 4B            1.37E-02   FBgn0028688       Regulatory particle non-ATPase 7             1.93E-03   FBgn0015778       Rasputin                                   3.14E-02
  FBgn0017579   Ribosomal protein L14                                  1.44E-02   FBgn0000181       Bicaudal                                     1.95E-03   FBgn0041775       Trailer hitch                              3.16E-02
  FBgn0000181   Bicaudal                                               1.62E-02   FBgn0035208       uncharacterized protein                      4.15E-03   FBgn0262743       Female sterile (2) Ketel                   3.30E-02
  FBgn0000308   Chickadee                                              2.19E-02   FBgn0261397       dilute class unconventional myosin           7.41E-03   FBgn0042134       Caprin                                     3.31E-02
  FBgn0003279   Ribosomal protein L4                                   2.56E-02   FBgn0003371       Shaggy                                       9.11E-03   **FBgn0000117**   **Armadillo**                              3.31E-02
  FBgn0030086   Chaperonin containing TCP1 subunit 2                   2.79E-02   FBgn0013770       Cysteine proteinase-1                        1.19E-02   FBgn0259173       Cornetto                                   3.38E-02
  FBgn0266446   uncharacterized protein                                2.83E-02   FBgn0001122       G protein alpha o subunit                    1.61E-02   FBgn0003371       Shaggy                                     3.46E-02
  FBgn0020235   ATP synthase, gamma subunit                            2.98E-02   FBgn0029969       uncharacterized protein                      1.64E-02   FBgn0020279       lingerer                                   3.53E-02
  FBgn0260639   Gamma-Tubulin at 23C                                   3.34E-02   **FBgn0000117**   **Armadillo**                                2.64E-02   FBgn0051716       CCR4-NOT transcription complex subunit 4   3.56E-02
  FBgn0024733   Ribosomal protein L10                                  3.42E-02   FBgn0010516       Walrus                                       2.77E-02   FBgn0266557       Kismet                                     3.65E-02
  FBgn0011640   Lark                                                   3.45E-02   FBgn0027108       Innexin 2                                    3.31E-02   FBgn0034181       uncharacterized protein                    3.82E-02
  FBgn0039713   Ribosomal protein S8                                   3.90E-02   FBgn0039704       Neyo                                         3.33E-02   FBgn0005771       No ocelli                                  4.54E-02
  FBgn0001092   Glyceraldehyde 3 phosphate dehydrogenase 2             3.92E-02   FBgn0032773       Fondue                                       3.61E-02   FBgn0283479       Alkaline phosphatase 1                     4.79E-02
  FBgn0010078   Ribosomal protein L23                                  3.96E-02   FBgn0030699       uncharacterized protein                      3.70E-02   FBgn0030699       uncharacterized protein                    4.85E-02
  FBgn0038805   Mitochondrial transcription factor A                   4.13E-02   FBgn0038914       Female-specific independent of transformer   4.12E-02                                                                
  FBgn0260442   Rhea                                                   4.18E-02                                                                                                                                          
  FBgn0032444   Chaperonin containing TCP1 subunit 4                   4.20E-02                                                                                                                                          
  FBgn0034968   Ribosomal protein L12                                  4.50E-02                                                                                                                                          
  FBgn0028697   Ribosomal protein L15                                  4.51E-02                                                                                                                                          
  FBgn0034654   Eukaryotic translation initiation factor 3 subunit k   4.87E-02                                                                                                                                          

FlyBase ID represents the gene ID for the corresponding protein. FDR is the false discovery rate calculated by QProt. Red text indicates proteins common to all three pull downs, bold indicates the known target Armadillo.

We first determined whether the lists of potential interactors were enriched for any Gene Ontology terms and found that the Sgg-PA and Sgg^CPTI002603^ lists were significantly enriched for processes involved in ribosome assembly, cytoplasmic translation and protein folding (adjusted p \<2e-06), whereas the Sgg-PB list showed no significant enrichment. While these enrichments may suggest that the presence of the YFP tag in the lines affects protein synthesis, slowing it to allow the fluorescent protein to fold, we note that in mammalian systems GSK-3β has been shown to complex with chaperones during maturation \[[@pone.0236679.ref048]\] and to colocalise with chaperone complexes in a Huntington's disease model \[[@pone.0236679.ref049]\]. Thus, whether these represent noise or biologically relevant interactions remains to be determined, however, we note that no such enrichments were observed with the Sgg-PB proteoform and loss of Sgg-PA proteoforms does not lead to upregulation of the stress response in our RNA-seq analysis, suggesting there is no general translational disruption in the Sgg-PA and CPTI lines.

In common to the 3 different tagged lines we detected significant enrichment of Bicaudal and CG10591 proteins (red in [Table 1](#pone.0236679.t001){ref-type="table"}). Along with its characterised maternal role in early segmentation, Bicaudal is widely expressed during embryogenesis where it has a role in translation via binding nascent peptides. CG10591 is a protein of unknown function. Encouragingly, with Sgg-PB and the CPTI lines we identified Armadillo (β-Catenin), a known Sgg substrate, as an interacting partner but not with Sgg-PA. With the CPTI line we also identified Shotgun, an E-Cadherin known to bind β-Catenin, and α-Catenin, which also interacts with Arm. Finally, the G protein α o subunit, known to be involved in Wnt signalling, \[[@pone.0236679.ref050]\] was identified with Sgg-PB. Thus for two of the lines we find evidence for predicted interactions. Specific to the Sgg-PB line we identified the gap junction protein Innexin 2 \[[@pone.0236679.ref051]\], known to localise with Sgg and E-Cadherin, along with the cell adhesion molecule Fasciclin 1 and Neyo, a component of the zona pellucida complex \[[@pone.0236679.ref052]\]. We also detected the interaction with Regulatory particle non-ATPase 7, which is involved in the ATP-dependent degradation of ubiquitinated proteins including CACT, an important component for the degradation of NF-kappa-B inhibitor or degradation of Cl that participates in the Hedgehog (Hh) signalling pathway. Together these interactions are consistent with the enrichment of Sgg-PB isoform at the cell membrane and also with known roles for Sgg in regulating aspects of cell junctions. In the case of Sgg-PA, we identified the Talin protein Rhea, the actin binding profilin Chickadee and Gamma Tubulin 23C, cytoskeletal components known to be expressed in the nervous system. Among other interactors of Sgg-PA associated with nervous system localisation we detected Lark \[[@pone.0236679.ref053]\], which mediates aspects of circadian clock output \[[@pone.0236679.ref054]\] and two subunits of the Chaperonin TCP complex (2 and 4) that are known to have roles in the nervous system. Together, these identified interacting proteins are consistent with the localisation of Sgg-PA to the CNS. Interestingly, the RNA-seq analysis of *sgg*^*isoA*^ mutants identified several misregulated components of the mitochondrial ATP synthesis pathway and our IPAC analysis identified the gamma subunit of ATP synthase along with the mitochondrial regulator TFAM, indicating a potential link with neural energy homeostasis. Taken together, the iPAC analysis identified several known Sgg interacting proteins, found little overlap between proteins enriched with the proteoform-specific pulldowns and indicates that Sgg is involved in diverse, tissue-specific processes in the embryo.

Lifespan and locomotor dysfunction in *sgg*^*isoA*^ mutants {#sec013}
-----------------------------------------------------------

While GSK-3 is a recognized target for the treatment of age related pathologies and multiple diseases, its role in the aging process remains unclear \[[@pone.0236679.ref055]\]. According to some studies, RNAi knockdown of *sgg* in *Drosophila* shortens lifespan or causes lethality \[[@pone.0236679.ref056]\]. However, these results are contradictory to expectations from earlier studies suggesting that lithium treatment extends lifespan via GSK-3 inhibition, determined using specific RNAi to mediate reduction in *sgg* expression \[[@pone.0236679.ref057]\]. In knock-out mice, loss of GSK-3β is embryonic lethal, whereas GSK-3α null mice exhibit shortened lifespan and increased age-related pathologies \[[@pone.0236679.ref058]\]. Given the apparent contradictory evidence of the role of *sgg* in lifespan, we investigated whether loss of the Sgg-PA proteoform, which is viable and fertile, positively or negatively influences life span in *Drosophila*.

We performed a standard survival analysis of *sgg*^*isoA*^ null males and females separately, along with matched flies from the progenitor strain. We found that homozygous *sgg*^*isoA*^ females showed significantly reduced survival (\~15%, p \<0.05) compared to controls and an even more sever reduction (\~25%, p\<0.05) in hemizygous males ([Fig 5A](#pone.0236679.g005){ref-type="fig"}). These results indicate that in flies as in mice, deletion of the Sgg-PA proteoform has a negative effect on longevity.

![*sgg*^*isoA*^ phenotypic assays.\
**(A)** Graph of lifespan from replicate lines of progenitor controls, *sgg*^*isoA*^ null females and males as indicated. Error bars represent standard deviation. (**B)** Graph of locomotor activity as measured by climbing assays with replicate lines of progenitor controls, *sgg*^*isoA*^ null females and males as indicated. Error bars represent standard deviation.](pone.0236679.g005){#pone.0236679.g005}

Since Sgg-PA is extensively expressed in the developing nervous system and GSK-3α mutant mice have nervous system phenotypes, we sought to determine whether the loss of this proteoform has effects on neural function in flies by looking at impairment in locomotor activity via climbing assays ([Fig 5B](#pone.0236679.g005){ref-type="fig"}). In homozygous females the loss of Sgg-PA resulted in a 40% decrease in locomotor activity across the lifespan with a similar reduction observed in hemizygous males. The maximum climbing activity was observed in 10 days old flies and was just over 75% for the control line and approximately 45% for the *sgg*^*isoA*^ null. The climbing activity gradually decreased over time and in 40 days old flies was reduced to 55% for the control line and 27% for *sgg*^*isoA*^ null flies ([Fig 5B](#pone.0236679.g005){ref-type="fig"}). These observations indicate that loss of the predominantly nervous system expressed Sgg-PA proteoform impairs motor function.

Taken together, our results indicate that although conditional modulation of GSK-3 levels may prolong lifespan or can mitigate the negative age-associated symptoms observed with diseases such as Alzheimer's or diabetes \[[@pone.0236679.ref055]\], the isoform specific knockout of a nervous system-specific proteoform results in reduced lifespan and locomotor defects. Given the positive impact of GSK-3 inhibition on multiple diseases ranging from neurological disorders to cancer, as well widespread therapeutic interventions targeting GSK-3, further studies are required to assess long-term effects on the aging process and the risks associated with nervous system impairment.

Taken together, our studies indicate that GSK3 performs complex functions mediated by multiple different spliced isoforms that generate functionally distinct proteins. At the level of proteoform expression we provide evidence of complex temporal and tissue specific protein localisation that presumably results from highly regulated tissue-specific splicing as well as evidence for the use of non-canonical transcriptional initiation. Our most striking finding is the major functional differences observed between the two most abundant 3' coding exons, with the short form mediating the well established essential roles for Sgg in development, whereas the long form has nervous specific expression and measurable functional roles in nervous system function. This situation is reminiscent of the divergent roles apparently played by GSK-3α and GSK-3β in mammalian systems. The identification of a different repertoire of interacting proteins for the major *Drosophila* GSK3 proteoforms may provide clues as to the differing roles played by the vertebrate orthologues and opens a route to understanding how this critical kinase can be deployed in different biological contexts.

Materials and methods {#sec014}
=====================

Cloning gRNAs {#sec015}
-------------

To generate the transgenic fly lines carrying the tagged isoforms, we used CRISPR/Cas9 technology as previously described \[[@pone.0236679.ref038]\]. We initially designed the insertion sites as indicated ([Fig 1](#pone.0236679.g001){ref-type="fig"}) and choose appropriate gRNAs ([S3 Table](#pone.0236679.s005){ref-type="supplementary-material"}) for cloning into pCDF3 or pCDF4 vectors \[[@pone.0236679.ref059]\]. Briefly, target specific sequences were synthesized and either 5′-phosphorylated annealed, and ligated into the *Bbs*I sites of pCDF3 or amplified by PCR for cloning into pCDF4 pre-cut with *Bbs*I.

Generation of donor vectors {#sec016}
---------------------------

Unless otherwise noted, cloning of donor vectors was performed with the Gibson Assembly Master Mix (New England Biolabs). PCR products were produced with the Q5 High-Fidelity 2X Master Mix (New England Biolabs). All inserts were verified by sequencing. Primers used for plasmid construction are listed in [S4 Table](#pone.0236679.s006){ref-type="supplementary-material"}.

Drosophila methods {#sec017}
------------------

Embryos were injected using standard procedures into the *THattP40* line expressing *nos*-Cas9 \[[@pone.0236679.ref060], [@pone.0236679.ref061]\]. 500 ng/μl of donor DNA in sterile dH~2~O was injected together with 100 ng/μl of gRNA plasmid. Individually selected surviving adults were crossed to *w*^*1118*^ and the progeny screened for fluorescence: positive flies were balanced and homozygous stocks established where possible (Primers used for genotyping are listed in [S5 Table](#pone.0236679.s007){ref-type="supplementary-material"}). Injections were performed by the Department of Genetics Fly Facility ([https://www.flyfacility.gen.cam.ac.uk](https://www.flyfacility.gen.cam.ac.uk/)). All fly stocks were maintained at 25°C on standard cornmeal medium. Embryos were collected from small cages on yeasted grape juice agar plates.

Immunostaining {#sec018}
--------------

Localization of tagged proteoforms in embryos was visualized by immunohistochemistry using Mouse Anti-FLAG M2 (F1804 Sigma), followed by biotinylated goat anti-Mouse IgG (*BA-9200*, Vector Laboratories) and the Vectastain ABC HRP Kit (PK-4000, Vector Laboratories) using standard protocols \[[@pone.0236679.ref062]\]. Embryos were mounted in glycerol and imaged using a Zeiss Axiphot.

Confocal microscopy {#sec019}
-------------------

For fluorescence imaging, embryos were collected, dechorionated and quickly fixed to avoid bleaching then mounted in glycerol. For live imaging, embryos were dechorionated and mounted in halocarbon oil. Images were acquired using a Leica SP8 confocal microscope (Leica microsystems) with appropriate spectral windows for mVenus and mCherry. images were processed with the Fiji software \[[@pone.0236679.ref063]\].

RNA-seq {#sec020}
-------

10-15hr embryos from a homozygous *sgg*^*isoA*^ stock and a control line were collected and processed for RNA-seq as described below. In the case of *sgg*^*isoB*^, non-fluorescent embryos from a cross between *sgg*^*isoB*^*/FM7-GFP* X *FM7-GFP/Y* were collected. In parallel, non-fluorescent embryos from a *+/FM7-GFP* X *FM7-GFP/Y* cross were also collected (FM7-GFP: FM7c, P{GAL4-twi.G}108.4, P{UAS-2xEGFP}AX).

Tissue was homogenised in 300 μl TRIzol with a motorised pellet pestle for 30 seconds. The sample volume was then increased to 1 ml, then 200 μl of Chloroform was added and vortexed. Samples were centrifuged at max speed for 15 minutes at room temperature and the upper phase transferred to a new 1.5 ml tube. The RNA was then precipitated with 0.8 volumes of Isopropanol and incubated at -20°C for 2 hours. The samples were then centrifuged at 4°C at maximum speed for 30 minutes to pellet the RNA. The pellet was then washed with 1 ml 70% ethanol and centrifuged cold for another 5 minutes. After complete removal of the ethanol the RNA was dried for 5 minutes and re-suspended in 20 μl DEPC-treated water. The concentration of samples was determined with the Qubit RNA HS Assay Kit and sample quality assessed with the Bioanalyzer and on 1% agarose gels. Sequencing libraries were prepared using the NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina. For each sample 100 ng total RNA were processed with the NEBNext Poly(A) mRNA Magnetic Isolation Module. For all reactions, half volumes were used throughout the protocol, with the exception of the AMPure bead clean-up step where washes were performed used the standard 200 μl 80% fresh Ethanol. Samples were barcoded and PCR amplifications were performed for 12 cycles. After Bioanalyzer quality control equal amount of sample libraries were pooled and submitted for Illumina single-end sequencing.

Fastq reads were aligned using tophat (v2.1.1) with Bowtie (version: 2.3.4.0) using the default parameters. Gene counts tables across samples were created with Rsubread (1.22.3) using dmel_r6.20.gtf and options GTF.featureType = \"exon\" and GTF.attrType = \"gene_id\" and default parameters. Read counts per experiment (*sgg*^*isoA*^ and *sgg*^*isoB*^ experiments were processed independently) were imported into edgeR (3.14.0) and filtered using the filterByExpr function with the default parameters (10397 genes were retained for *sgg*^*isoA*^ and 10693 genes for *sgg*^*isoB*^). The data was then normalised in limma (3.28.21) using limma-voom. Significant genes were identified fitting a linear model (lmFit) and empirical Bayes method (eBayes) \[[@pone.0236679.ref064]--[@pone.0236679.ref067]\]. Genes were considered significant differential expressed with fdr \< = 0.05 and logFC \> = \|0.7\|. RNA-seq data are available from GEO (GSE139040).

iPAC-MS {#sec021}
-------

Embryos from 8--20 hr collections were washed from agar plates with tap water, collected in 100 μm sieves, rinsed in the same solution to remove any yeast, dechorionated in 50% bleach for 1 min, rinsed again and placed on ice. Where necessary, washed embryos were frozen at −80°C until a sufficient quantity was collected. For each purification, \~200 μl wet-volume of embryos were manually homogenized with a 2 ml Dounce homogenizer in 1 ml of extraction buffer (50 mM Tris, pH 7.5, 125 mM NaCl, 1.5 mM MgCl~2~, 1 mM EDTA, 5% Glycerol, 0.4% Igepal CA-630, 0.5% digitonin and 0.1% Tween 20) and processed essentially as previously described \[[@pone.0236679.ref047]\]. Samples were independently immunopurified using StrepII, FLAG and YFP.

ANTI-FLAG^®^ M2 affinity gel (Sigma) and *Strep*-Tactin® Superflow® resin (IBA) were used to capture each FLAG-tagged or StrepII-tagged bait and its binding partners, respectively \[[@pone.0236679.ref047]\]. For pulldown of fluorescently tagged proteins (YFP), anti-GFP mAb agarose resin (MBL International) was used. Briefly, protein concentration estimation in the embryo lysate was performed using a DC assay (Bio-Rad). The lysate was divided equally into three parts (6 mg total protein per pulldown), to which each resin, pre-washed in extraction buffer, was added. Following 2 h of incubation at 4°C on a rotating wheel, the resin was washed three times in extraction buffer. Immunoprecipitates were eluted twice each, using 100 μg/ml 3xFLAG peptide (Sigma) in lysis buffer for FLAG immunoprecipitates and 10 mM desthiobiotin in lysis buffer for *Strep*-Tactin immunoprecipitates; each for 10 minutes at 4°C. Anti-GFP resin immunoprecipitates were eluted in 100 mM glycine-HCl, pH 2.5 with gentle agitation for 30 seconds, followed by immediate neutralization in 1 M Tris-HCl, pH 10.4.

Purification of the baits was confirmed via immunoblots (data not shown) and samples were prepared for mass spectrometric analysis using in-gel digestion, allowing the sample to enter 2 cm into an SDS-PAGE gel. Gels were fixed and stained with colloidal Coomassie stain, after which the protein-containing band was excised and cut into two equally sized parts. Each band was destained, reduced with dithiothreitol, alkylated with iodoacetamide and subjected to tryptic digest for 16 hours at 37°C. Approximately 1 μg of peptides from each digested band was analysed using LC-MS/MS on a Q Exactive mass spectrometer (ThermoFisher Scientific), as previously described \[[@pone.0236679.ref068]\].

For label-free quantification (LFQ), data were processed using MaxQuant (version 1.6.3.4) \[[@pone.0236679.ref069]\]. Raw data were searched against protein sequences contained in the all translation database obtained from FlyBase release FB2017_06 dmel_r6.19 at (<ftp://ftp.flybase.net/releases/FB2017_06/dmel_r6.19/fasta/>). The database was customised with the addition of the Uniprot proteome for *Wolbachia pipientis wMel* (<https://www.uniprot.org/uniprot/?query=proteome:UP000008215>). Within MaxQuant, searches were performed against a reversed decoy dataset and a set of known contaminants. Default search parameters were used with digestion using trypsin allowing two missed cleavages and minimum peptide lengths of six. Carbamidomethyl Cysteine was specified as a fixed modification. Oxidation of Methionine, N-term protein Acetylation and Phosphorylation of Serine, Threonine and Tyrosine were specified as variable modifications. Additionally, "match between runs" was enabled with fractions specified to limit matching to occur only between replicates of the same bait and tag combination.

Identification of interacting partners was performed with QProt \[[@pone.0236679.ref070]\]. Input for QProt was created from the MaxQuant "proteinGroups.txt" output file. Individually for each bait and tag combination, proteins that were not reverse decoys or potential contaminants were extracted where there was an LFQ reported for at least one tagged replicate. The LFQ values for proteins detected in the tagged bait pulldowns were matched with the corresponding tag in the wild type pulldown. Enrichment analysis was then performed for each bait and tag combination against the corresponding wild type using qprot-param with burn-in set to 10,000 and number of iterations set to 100,000. The QProt tool getfdr was used to calculate the FDR of enrichment. Any proteins enriched in pulldowns using at least two of the three tags with an FDR of less than 0.05 were classed as enriched and the highest FDR from the replicates is reported.

Lifespan determination {#sec022}
----------------------

Adult female and male flies were collected shortly after eclosion and separated into 5 cohorts of 100 flies (500 total) for each genotype. Flies were maintained at 25°C and transferred to fresh food every 2 days at which time the number of surviving flies was recorded.

Locomotor behaviour {#sec023}
-------------------

Adult female and male flies were collected shortly after eclosion and separated into 10 cohorts consisting of 10 flies (100 total) for each genotype. Flies were maintained at 25°C and transferred to fresh food every 3 days. For the climbing assay, each cohort was transferred to an empty glass cylinder (diameter, 2.5 cm; height, 20 cm), and allowed to acclimatize for 5 min. For each trial, flies were tapped down to the bottom of the vial, and the percentage of flies able to cross an 8-cm mark successfully within 10 s was recorded as the climbing index. Five trials were performed for each cohort, with a 1-min recovery period between each trial. Climbing assays were performed 1, 5, 10, 30 and 40 days after eclosion.

Supporting information {#sec024}
======================

###### 

**(A-C)** anti-FLAG immunohistochemistry of Sgg-PA expression in the ventral neuroectoderm of a stage 10 embryo **(A)**, the brain from a stage 16 embryo **(B)** and the head region showing various sensory organs **(C)**. Scale = 20μm. **(D and E)** dorsal view of a stage 16 Sgg-PB embryo showing expression in the gut (arrows) and mesoderm (arrowheads), Scale = 100μm, and lateral view of hindgut **(E)** Scale = 20μm. **(F)** blastoderm embryo expressing mCherry tagged Sgg-PB and YFP tagged Sgg-PA, demonstrating ubiquitous Sgg-PB, the YFP signal represents yolk cell autofluorescence, Scale = 100μm. **(G)** close up of punctate epidermal expression in a Sgg-PB mCherry stage 16 embryo, Scale = 20μm.

(PDF)

###### 

Click here for additional data file.

###### Immunohistochemistry of tagged Sgg proteoforms.

**A-U)** Anti-flag staining of embryos with the indicated tagged proteoforms at stage 5--6 (blastoderm, left column), 10--11 (germband extension, middle column) and 16 (late embryogenesis, right column). All embryos oriented anterior to the left dorsal to the top except U, which is a dorsal view. See text for full details of expression. **(D and E)**, arrows = meseoderm; **(F)** arrow = salivary gland, arrowheads = malphigian tubules, asterisk = posterior spiracles; **(H)** arrow = mesoderm; **(I)** arrow = hindgut; **(L)** arrow = hindgut, arrowhead = foregut, white arrowhead = pharynx; **(N)** arrow = mesoderm; **(O)** arrow = hindgut, arrowhead = proventriculus; **(Q)** arrow = mesoderm; **(R)** arrow = hindgut, arrowhead = anterior midgut; **(U)** arrow = salivary gland, arrowhead = proventriculus. Scale bar in A = 100μm. **(V-Y)** Close up dorsal views highlighting: **(V)** Sgg-PD expression in the salivary gland (arrow) and proventriculus (arrowhead); **(W)** Sgg-PG in the foregut (arrowhead) and anterior region of the pharynx (arrow); **(X)** prominent Sgg-PO expression in the proventriculus (arrow) and **(Y)** Sgg-PP in the hindgut (arrow). Scale bar in V = 20μm applies to V-Y.

(PDF)

###### 

Click here for additional data file.

###### Protein and transcript isoforms encoded by the *D*. *melanogaster sgg* locus.

(TXT)

###### 

Click here for additional data file.

###### Transcripts with significant expression changes in *sgg*^*isoA*^ and *sgg*^*isoB*^ embryos compared with stage matched progenitors.

(TXT)

###### 

Click here for additional data file.

###### List of gRNAs used to generate CRISPR/Cas9 mediated HDR and transgenic fly lines.

(XLSX)

###### 

Click here for additional data file.

###### List of primers used to generate donor vectors for homology mediated recombination via CRISPR/Cas9.

(TXT)

###### 

Click here for additional data file.

###### List of primers used for genotyping engineered flies.

(TXT)

###### 

Click here for additional data file.

10.1371/journal.pone.0236679.r001

Decision Letter 0

Klymkowsky

Michael

Academic Editor

© 2020 Michael Klymkowsky

2020

Michael Klymkowsky

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

24 Jun 2020

PONE-D-20-12754

Characterisation of protein isoforms encoded by the Drosophila Glycogen Synthase Kinase 3 gene shaggy

PLOS ONE

Dear Dr. Russell,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The two reviewers have made a number of comments that should be addressed and that I think will greatly enhance the impact of what is likely to be an important contribution.  Please address them in your revision - particularly with regards that quality and interpretability pointed out by review \#1.   

Please submit your revised manuscript by Aug 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Michael Klymkowsky, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3\. Please include a copy of Table 1 which you refer to in your text on page 8 and 9.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript bravely addresses the complexity of the shaggy (Sgg) gene, which encodes multiple variations of the Drosophila GSK-3 primarily through alternative splicing. The authors have knocked in tagged versions for each splice form, examined protein expression patterns for multiple splice forms, and compared phenotypes for loss of the two major proteoforms. This work may provide insights into the functions of GSK-3 across species and may help to define the roles of Sgg in development, lifespan, and motor function. However, the manuscript could be revised to improve clarity, improve documentation of the figures and data, and provide standard controls that they likely have in hand already.

1\. Major concerns are the quality of the IHC images in Figures 2 and 4. Figure 2 has no controls for background staining and it is difficult to discern signal from background in many of the panels. The figure needs a negative control such as no primary antibody, especially for Fig2J-O, reportedly showing Sgg-PB expression. For example, Fig 2, Panel J (presumably ubiquitous expression) is difficult to distinguish from Fig 2, panel A (presumably background). The figures are also not well annotated; arrows or other annotation of the figures would helpful for these less than obvious expression patterns. The magnification changes from one panel to the next, so they should also include scale bars for every photomicrograph.

2\. Figures 2G and 2H reportedly show cytoplasmic expression that was "particularly concentrated in the vicinity of the cell membrane." This subcellular pattern is not clear. It is not even clear (to this observer) that staining in panel 2G is intracellular vs trapped between what appear to be a cluster of cells. Protein localization data should be improved with higher resolution methods. For example, a higher resolution confocal image with a counter stain for cellular landmarks (plasma membrane and nuclear markers for example) would be helpful to make their conclusions more convincing.

3\. This is a stylistic suggestion, not a critique: Why not rearrange figures 2 and 3 to pair Flag/IHC (Fig 2) with YFP/IF (Fig 3 A-D) by proteoform rather than sorting by imaging method? For Figure 3E-I, they could then show the YFP and mCherry as separate images as well as showing the overlap. This is just a suggestion that I would leave up to the authors.

4\. The authors should discuss the original work of Ruel et al (Nature 1993) showing that mammalian Gsk3b can rescue sgg null phenotypes, which seems to suggest that alternatively spliced forms are not essential. Perhaps this is a more nuanced point but this point should be discussed (Ruel et al was cited but this point was not discussed).

5\. Figure 4, as in Figure 2, does not have a negative control, and it is difficult to distinguish background from real staining. Furthermore, relevant structures are not highlighted, there are no scale bars, and more generally, this is not a particularly informative or useful figure. They could remove this figure without detriment to the manuscript and just describe the results in the text, or, if the journal allows, move this to supplementary data (but would still need background control, scale bars, and clearer labeling of structures).

6\. Table 1 with a list of interacting proteins was not in the downloaded PDF. This review cannot be completed until all data are available.

Minor comments:

7\. Gene names in Figure 5B are pixelated and illegible.

8\. Rather than referring to developmental stages by numbers, the authors could use more descriptive names for the stages shown so that readers unfamiliar with Drosophila staging can appreciate the work more readily?

9\. Page 3: "in Xenopus, knockdown results in axis formation defects \[11\]." These experiments involved expression of a kinase-dead mutant GSK-3; they were not knockdowns. Similar "dominant-negative" experiments in Xenopus were reported by He et al and by Pierce et al.

10\. "In contrast to vertebrates, the Drosophila genome contains a single GSK-3 locus..." What about Gasket, similar to GSK-3 and sgg but expressed from a distinct locus?

Reviewer \#2: This study follows up some 30 years after the original publications of the cloning of shaggy/zeste-white3 by the Simpson and Perrimon groups and uses insertions of tags into various exons to trace the various potential isoforms of the single shaggy gene. The authors then describe the expression patterns of the protein variants, demonstrating that they exist and also perform some proteomic analysis. They also selectively delete the two major isoforms, Sgg-PA and Sgg-PB to evaluate the effect on viability, longevity and in a behavioural test. This is a complete and compelling analysis that significantly enhances understanding of the shaggy locus.

Minor points:

1\. The anti-FLAG immunohistochemistry in figure 2 has a significant background and it would be advantageous to show immunoblotting of the isoforms from the embryos to indicate the relative levels of expression of the different proteoforms. This would also be useful to do for the Sgg-PA and Sgg-PB knockouts (se evaluate any interactive effect on expression).

2\. The authors perhaps go too far in comparing the Sgg-PA and Sgg-PB proteoforms with the two mammalian isoforms encoded by different genes). In the latter case, both are ubiquitously expressed and the similarities may be coincidental.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Jim Woodgett

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236679.r002
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We thank the reviewers for their time and effort on our manuscript and the helpful comments. Below we address the points raised by the editorial team and each reviewer. We hope that the revisions to the manuscript and figures along with the response below are satisfactory.

Kind regards

Steve Russell (on behalf of the authors)

Journal

1\. Formatted as requested

2\. "Data not shown" removed, the statement is not necessary since the very phenotypes alluded to are minor and we regard them as insignificant. We have deposited the images on out University data store <https://doi.org/10.17863/CAM.54850> .

3\. Table 1 included, apologies for the omission.

1\. Major concerns are the quality of the IHC images in Figures 2 and 4. Figure 2 has no controls for background staining and it is difficult to discern signal from background in many of the panels. The figure needs a negative control such as no primary antibody, especially for Fig2J-O, reportedly showing Sgg-PB expression. For example, Fig 2, Panel J (presumably ubiquitous expression) is difficult to distinguish from Fig 2, panel A (presumably background). The figures are also not well annotated; arrows or other annotation of the figures would helpful for these less than obvious expression patterns. The magnification changes from one panel to the next, so they should also include scale bars for every photomicrograph.

We note that 2 A, D and G shows anti-FLAG staining in wild type embryos with no tags, this provides the standard background control for the specificity of the antibody (also see response to reviewer 2 below). The Sgg-PB protein and transcript have a well described strong maternal contribution. In support of the antibody staining we now include a live confocal image of the mCherry tagged Sgg-PB at the blastoderm stage confirming strong and ubiquitous staining. With respect to the epidermal and mesodermal staining with Sgg-PB, we include Sgg-PB\[YFP\] close up of the mesoderm (Fig 2O) and Sgg-PB\[mCh\] close up of the epidermis, again supporting results with the FLAG. Finally, in Fig 2J we show a wild type embryo imaged in the YFP channel showing no signal (apart from well known gut autofluorescence). Taken together we believe the combination of anti-FLAG immunohistochemistry and live confocal imaging are consistent with the localisations we report.

We have added annotations and scale bars to all figures

2\. Figures 2G and 2H reportedly show cytoplasmic expression that was "particularly concentrated in the vicinity of the cell membrane." This subcellular pattern is not clear. It is not even clear (to this observer) that staining in panel 2G is intracellular vs trapped between what appear to be a cluster of cells. Protein localization data should be improved with higher resolution methods. For example, a higher resolution confocal image with a counter stain for cellular landmarks (plasma membrane and nuclear markers for example) would be helpful to make their conclusions more convincing.

Given the current limitations we face in the laboratory, we have elected to remove the statement relating to membrane association and on page 5 have changed the text to read "Looking more closely we observed that in the chordotonal organs staining was associated with the cell bodies and extended into the ciliated endings. (arrows in Figs 2M and P)."

3\. This is a stylistic suggestion, not a critique: Why not rearrange figures 2 and 3 to pair Flag/IHC (Fig 2) with YFP/IF (Fig 3 A-D) by proteoform rather than sorting by imaging method? For Figure 3E-I, they could then show the YFP and mCherry as separate images as well as showing the overlap. This is just a suggestion that I would leave up to the authors.

We thank the reviewer for these comments and suggestions and have rejigged the figures. Fig 2 now shows the immunohistochemistry and live confocal images of Sgg-PA and Sgg-PB. Scalebars and arrows have been added for clarity. Some more detailed images are provided in Sup Fig 1

The new Fig 3 included the reciprocal labelling and higher magnification views, scale bars have been added.

The old Figure 3 detailing expression of the other tagged proteoforms has been moved to Supp Fig 2 and has been annotated.

4\. The authors should discuss the original work of Ruel et al (Nature 1993) showing that mammalian Gsk3b can rescue sgg null phenotypes, which seems to suggest that alternatively spliced forms are not essential. Perhaps this is a more nuanced point but this point should be discussed (Ruel et al was cited but this point was not discussed).

The rescue experiments in the Ruel et al paper are not straightforward, while the assays used show that a Sgg-PB proteoform (Sgg10) can fully rescue the sggD127 null allele and sggb12 (an allele lacking some but not all isoforms), Gsk-3b (but not Gsk-3a) only provides partial rescue.

We modified the text on Pg 4 to insert: "Rescue experiments in Drosophila indicate that expression of a Sgg-PB isoform can fully rescue sgg null phenotypes and that mammalian GSK-3β but not GSK-3α can provide partial rescue of some, but not all null phenotypes, emphasising the difference between the mammalian genes and pointing to functional differences between Sgg proteoforms \[27\]."

5\. Figure 4, as in Figure 2, does not have a negative control, and it is difficult to distinguish background from real staining. Furthermore, relevant structures are not highlighted, there are no scale bars, and more generally, this is not a particularly informative or useful figure. They could remove this figure without detriment to the manuscript and just describe the results in the text, or, if the journal allows, move this to supplementary data (but would still need background control, scale bars, and clearer labeling of structures).

As suggested we have moved this to Supplementary Figure 2, added scale bars and included some annotations. The negative control remains wild type embryos stained with anti-FLAG

6\. Table 1 with a list of interacting proteins was not in the downloaded PDF. This review cannot be completed until all data are available.

We profusely apologise for this oversight

Minor comments:

7\. Gene names in Figure 5B are pixelated and illegible.

We have generated a much higher resolution version and apologise for the loss of resolution during file conversion.

8\. Rather than referring to developmental stages by numbers, the authors could use more descriptive names for the stages shown so that readers unfamiliar with Drosophila staging can appreciate the work more readily?

While we note this is standard nomenclature in Drosophila (much like vertebrate embryologists use number of somites),we added clarifications, particularly in the figure legends.

9\. Page 3: "in Xenopus, knockdown results in axis formation defects \[11\]." These experiments involved expression of a kinase-dead mutant GSK-3; they were not knockdowns. Similar "dominant-negative" experiments in Xenopus were reported by He et al and by Pierce et al.

We changed the text on page 3 to "expression of a kinase dead version of GSK-3β resulted in axis formation defects \[11\]"

10\. "In contrast to vertebrates, the Drosophila genome contains a single GSK-3 locus..." What about Gasket, similar to GSK-3 and sgg but expressed from a distinct locus?

Pg 3 -- inserted "A second GSK-3 is encoded by the gasket locus, a retrotransposed gene whose expression is largely restricted to the testis (Kalamegham, R et al 2007), and is not considered further here"

Reviewer \#2: This study follows up some 30 years after the original publications of the cloning of shaggy/zeste-white3 by the Simpson and Perrimon groups and uses insertions of tags into various exons to trace the various potential isoforms of the single shaggy gene. The authors then describe the expression patterns of the protein variants, demonstrating that they exist and also perform some proteomic analysis. They also selectively delete the two major isoforms, Sgg-PA and Sgg-PB to evaluate the effect on viability, longevity and in a behavioural test. This is a complete and compelling analysis that significantly enhances understanding of the shaggy locus.

Minor points:

1\. The anti-FLAG immunohistochemistry in figure 2 has a significant background and it would be advantageous to show immunoblotting of the isoforms from the embryos to indicate the relative levels of expression of the different proteoforms. This would also be useful to do for the Sgg-PA and Sgg-PB knockouts (se evaluate any interactive effect on expression).

We are unable to complete satisfactory immunoblotting experiments due to current limitations at our institution, we have pilot data, not suitable for publication, that supports our analysis. It shows a cross-reacting band in wild type with anti-FLAG that is not present with StrepII detection, presumably accounting for the weak background we show. These preliminary data are available from the University data repository (<https://doi.org/10.17863/CAM.54850>). Taken together, we strongly suggest that the fluorescent imaging -- which is clearly independent of the antibody staining -- is entirely consistent with the localisations we report and that the preliminary Western data further support the validity of the images we wish to publish.

2\. The authors perhaps go too far in comparing the Sgg-PA and Sgg-PB proteoforms with the two mammalian isoforms encoded by different genes). In the latter case, both are ubiquitously expressed and the similarities may be coincidental.

It may be that the similarities are coincidental, however, the evidence we describe indicates that GSK-3α and GSK-3β are not functionally equivalent: GSK-3α mutants are lethal and are obviously not rescued by GSK-3β, and we note that the work reported in Barrell et al (2012) Novel Reporter Alleles of GSK-3α and GSK-3β. (<https://doi.org/10.1371/journal.pone.0050422>) indicates that the mouse isoforms show differential expression.

The presence of a related amino-acid extension on Sgg-PA and GSK-3a, the non-essential nature of null mutations inthese proteoforms and the nervous system phenotypes, we believe are worth forwarding the hypothesis that they may be related.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors completely addressed the concerns that I had raised. .

Reviewer \#2: The authors have addressed or explained the issues raised (e.g. difficulty in performing experiments due to the pandemic).

Minor note; the DOI link for the preliminary data was broken (<https://doi.org/10.17863/CAM.54850>) and the GSK3 alpha lethality is beta lethality - but this error is only in the response to reviewers letter, not the manuscript, which has it the right way around.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: **Yes: **Jim Woodgett
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